{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "fa6691ef",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/hershit.rustagi/Documents/MajorProject/.venv/lib/python3.9/site-packages/urllib3/__init__.py:35: NotOpenSSLWarning: urllib3 v2 only supports OpenSSL 1.1.1+, currently the 'ssl' module is compiled with 'LibreSSL 2.8.3'. See: https://github.com/urllib3/urllib3/issues/3020\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import requests\n",
    "from tqdm import tqdm\n",
    "from scipy.stats import ttest_ind\n",
    "from IPython.display import display"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "db931ab6",
   "metadata": {},
   "outputs": [],
   "source": [
    "early_file = '/Users/hershit.rustagi/Downloads/early_stage_gene_expression.csv'\n",
    "late_file = '/Users/hershit.rustagi/Downloads/late_stage_gene_expression.csv'\n",
    "normal_file = '/Users/hershit.rustagi/Downloads/normal_gene_expression.csv'\n",
    "\n",
    "df_early_raw = pd.read_csv(early_file, index_col=0)\n",
    "df_late_raw = pd.read_csv(late_file, index_col=0)\n",
    "df_normal_raw = pd.read_csv(normal_file, index_col=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "13a8d5a8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ”„ Transposing Early data\n",
      "ðŸ”„ Transposing Late data\n",
      "ðŸ”„ Transposing Normal data\n"
     ]
    }
   ],
   "source": [
    "for label, df in zip(['Early', 'Late', 'Normal'], [df_early_raw, df_late_raw, df_normal_raw]):\n",
    "    if df.shape[0] > df.shape[1]:\n",
    "        print(f\"ðŸ”„ Transposing {label} data\")\n",
    "        if label == 'Early':\n",
    "            df_early_raw = df.T\n",
    "        elif label == 'Late':\n",
    "            df_late_raw = df.T\n",
    "        else:\n",
    "            df_normal_raw = df.T\n",
    "\n",
    "df_early = df_early_raw.select_dtypes(include=[np.number])\n",
    "df_late = df_late_raw.select_dtypes(include=[np.number])\n",
    "df_normal = df_normal_raw.select_dtypes(include=[np.number])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "3f8e616e",
   "metadata": {},
   "outputs": [],
   "source": [
    "def calculate_differential_expression(df_condition, df_normal, condition_name):\n",
    "    if df_condition.shape[1] != df_normal.shape[1]:\n",
    "        raise ValueError(\"Mismatch in number of genes.\")\n",
    "    \n",
    "    genes = df_condition.columns\n",
    "    mean_cond = df_condition.mean(axis=0)\n",
    "    mean_normal = df_normal.mean(axis=0)\n",
    "    log2fc = np.log2((mean_cond + 1e-6) / (mean_normal + 1e-6))\n",
    "    \n",
    "    p_values = []\n",
    "    for gene in genes:\n",
    "        try:\n",
    "            stat, p = ttest_ind(df_condition[gene], df_normal[gene], equal_var=False, nan_policy='omit')\n",
    "        except Exception:\n",
    "            p = np.nan\n",
    "        p_values.append(p)\n",
    "\n",
    "    result = pd.DataFrame({\n",
    "        'Gene': genes,\n",
    "        f'Mean_{condition_name}': mean_cond.values,\n",
    "        'Mean_Normal': mean_normal.values,\n",
    "        f'Log2_Fold_Change_{condition_name}': log2fc.values,\n",
    "        f'P_Value_{condition_name}': p_values\n",
    "    })\n",
    "    \n",
    "    result.dropna(subset=[f'P_Value_{condition_name}'], inplace=True)\n",
    "    result[f'Significant_{condition_name}'] = (\n",
    "        ((result[f'Log2_Fold_Change_{condition_name}'] > 1) & (result[f'P_Value_{condition_name}'] < 0.05)) |\n",
    "        ((result[f'Log2_Fold_Change_{condition_name}'] < -1) & (result[f'P_Value_{condition_name}'] < 0.05))\n",
    "    )\n",
    "    \n",
    "    return result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "12ee34b1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ”¬ Running Early vs Normal Analysis...\n",
      "\n",
      "\n",
      "âœ… Top 10 Genes with Log2FC > 1 or < -1 and P-Value < 0.05 (Early):\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/hershit.rustagi/Documents/MajorProject/.venv/lib/python3.9/site-packages/scipy/stats/_axis_nan_policy.py:531: RuntimeWarning: Precision loss occurred in moment calculation due to catastrophic cancellation. This occurs when the data are nearly identical. Results may be unreliable.\n",
      "  res = hypotest_fun_out(*samples, **kwds)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Gene</th>\n",
       "      <th>Log2_Fold_Change_Early</th>\n",
       "      <th>P_Value_Early</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>19116</th>\n",
       "      <td>canctyp</td>\n",
       "      <td>19.931570</td>\n",
       "      <td>0.000000e+00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2956</th>\n",
       "      <td>LGI3</td>\n",
       "      <td>-1.378339</td>\n",
       "      <td>2.108652e-148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12395</th>\n",
       "      <td>CNTN6</td>\n",
       "      <td>-1.471978</td>\n",
       "      <td>1.270197e-142</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13177</th>\n",
       "      <td>GPM6A</td>\n",
       "      <td>-1.249001</td>\n",
       "      <td>6.067808e-112</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15803</th>\n",
       "      <td>RS1</td>\n",
       "      <td>-1.632851</td>\n",
       "      <td>2.066936e-104</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2912</th>\n",
       "      <td>EPYC</td>\n",
       "      <td>2.689454</td>\n",
       "      <td>2.662058e-48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2420</th>\n",
       "      <td>PTPRH</td>\n",
       "      <td>1.602916</td>\n",
       "      <td>3.063599e-48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8473</th>\n",
       "      <td>C6orf126</td>\n",
       "      <td>4.372324</td>\n",
       "      <td>4.072227e-48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6116</th>\n",
       "      <td>CDC25C</td>\n",
       "      <td>1.443946</td>\n",
       "      <td>5.243554e-48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10484</th>\n",
       "      <td>NUF2</td>\n",
       "      <td>1.040881</td>\n",
       "      <td>7.282882e-48</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows Ã— 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "           Gene  Log2_Fold_Change_Early  P_Value_Early\n",
       "19116   canctyp               19.931570   0.000000e+00\n",
       "2956       LGI3               -1.378339  2.108652e-148\n",
       "12395     CNTN6               -1.471978  1.270197e-142\n",
       "13177     GPM6A               -1.249001  6.067808e-112\n",
       "15803       RS1               -1.632851  2.066936e-104\n",
       "...         ...                     ...            ...\n",
       "2912       EPYC                2.689454   2.662058e-48\n",
       "2420      PTPRH                1.602916   3.063599e-48\n",
       "8473   C6orf126                4.372324   4.072227e-48\n",
       "6116     CDC25C                1.443946   5.243554e-48\n",
       "10484      NUF2                1.040881   7.282882e-48\n",
       "\n",
       "[100 rows x 3 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ”¬ Running Late vs Normal Analysis...\n",
      "\n",
      "\n",
      "âœ… Top 10 Genes with Log2FC > 1 or < -1 and P-Value < 0.05 (Late):\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/hershit.rustagi/Documents/MajorProject/.venv/lib/python3.9/site-packages/scipy/stats/_axis_nan_policy.py:531: RuntimeWarning: Precision loss occurred in moment calculation due to catastrophic cancellation. This occurs when the data are nearly identical. Results may be unreliable.\n",
      "  res = hypotest_fun_out(*samples, **kwds)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Gene</th>\n",
       "      <th>Log2_Fold_Change_Late</th>\n",
       "      <th>P_Value_Late</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>19116</th>\n",
       "      <td>canctyp</td>\n",
       "      <td>20.931569</td>\n",
       "      <td>0.000000e+00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16588</th>\n",
       "      <td>SGCG</td>\n",
       "      <td>-1.727535</td>\n",
       "      <td>1.667709e-66</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15767</th>\n",
       "      <td>C10orf67</td>\n",
       "      <td>-1.957882</td>\n",
       "      <td>9.162859e-66</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15803</th>\n",
       "      <td>RS1</td>\n",
       "      <td>-1.722170</td>\n",
       "      <td>3.544363e-65</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13177</th>\n",
       "      <td>GPM6A</td>\n",
       "      <td>-1.332833</td>\n",
       "      <td>5.258891e-60</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5089</th>\n",
       "      <td>MND1</td>\n",
       "      <td>1.424401</td>\n",
       "      <td>3.057802e-38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12694</th>\n",
       "      <td>SYT12</td>\n",
       "      <td>1.500582</td>\n",
       "      <td>3.814931e-38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17545</th>\n",
       "      <td>SH3GL2</td>\n",
       "      <td>-1.530504</td>\n",
       "      <td>4.806491e-38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3934</th>\n",
       "      <td>COL11A1</td>\n",
       "      <td>1.858244</td>\n",
       "      <td>5.377216e-38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3083</th>\n",
       "      <td>ADCY8</td>\n",
       "      <td>-2.342547</td>\n",
       "      <td>6.444636e-38</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows Ã— 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "           Gene  Log2_Fold_Change_Late  P_Value_Late\n",
       "19116   canctyp              20.931569  0.000000e+00\n",
       "16588      SGCG              -1.727535  1.667709e-66\n",
       "15767  C10orf67              -1.957882  9.162859e-66\n",
       "15803       RS1              -1.722170  3.544363e-65\n",
       "13177     GPM6A              -1.332833  5.258891e-60\n",
       "...         ...                    ...           ...\n",
       "5089       MND1               1.424401  3.057802e-38\n",
       "12694     SYT12               1.500582  3.814931e-38\n",
       "17545    SH3GL2              -1.530504  4.806491e-38\n",
       "3934    COL11A1               1.858244  5.377216e-38\n",
       "3083      ADCY8              -2.342547  6.444636e-38\n",
       "\n",
       "[100 rows x 3 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ” Final Combined Top 10 Genes from Early/Late Analyses:\n",
      "['MYEOV', 'C13orf36', 'PTPRQ', 'BCL2L10', 'ZYG11A', 'EPYC', 'DVWA', 'LOC100131726', 'C10orf67', 'MGC27382', 'CD300LG', 'LOC283392', 'HHIPL2', 'HIST1H2AM', 'DLGAP5', 'RBP2', 'YBX2', 'IL1RAPL2', 'NETO1', 'KRTAP4-1', 'GPD1', 'GKN2', 'DUSP13', 'ACADL', 'LHFPL3', 'ADCY8', 'MYOC', 'LRRC36', 'LOC149620', 'ASPA', 'ACTN2', 'C5orf46', 'C1orf65', 'ONECUT1', 'PLEKHN1', 'KIF4A', 'GRIK4', 'E2F8', 'CNTN6', 'NRG3', 'RSPO1', 'GRIA1', 'SYT12', 'SCUBE1', 'PRAME', 'TRPM8', 'CYP3A7', 'ARSH', 'CPB2', 'TRHDE', 'DMBX1', 'C11orf86', 'DLL3', 'IHH', 'CLDN18', 'F11', 'DEPDC1', 'OVCH2', 'CABYR', 'LOC645323', 'LOC399815', 'MCM10', 'CCDC141', 'SLC6A13', 'GYPE', 'UPK3B', 'RS1', 'CAV3', 'MND1', 'FIGF', 'C6orf126', 'AKR7A3', 'PPP1R14D', 'TCEAL2', 'CST1', 'CHRNA2', 'EXO1', 'ZNF695', 'MUSK', 'C6orf155', 'ITLN2', 'GPM6A', 'C1orf182', 'CA4', 'GNGT1', 'HOXC13', 'ANGPTL7', 'AGBL1', 'canctyp', 'PITX2', 'WNT3A', 'NEIL3', 'FAM150B', 'RSPO2', 'LHFPL5', 'RASAL1', 'KISS1R', 'CDC45', 'SGCG', 'MMP11']\n"
     ]
    }
   ],
   "source": [
    "# ---------------- Run Analysis Summary + Publish Top Genes ----------------\n",
    "try:\n",
    "    # EARLY vs NORMAL\n",
    "    print(\"\\nðŸ”¬ Running Early vs Normal Analysis...\\n\")\n",
    "    early_results = calculate_differential_expression(df_early, df_normal, 'Early')\n",
    "\n",
    "    print(\"\\nâœ… Top 10 Genes with Log2FC > 1 or < -1 and P-Value < 0.05 (Early):\")\n",
    "    top10_early_significant_genes = early_results[early_results['Significant_Early'] == True] \\\n",
    "        .sort_values(by='P_Value_Early') \\\n",
    "        .head(100)\n",
    "    display(top10_early_significant_genes[['Gene', 'Log2_Fold_Change_Early', 'P_Value_Early']])\n",
    "\n",
    "    # LATE vs NORMAL\n",
    "    print(\"\\nðŸ”¬ Running Late vs Normal Analysis...\\n\")\n",
    "    late_results = calculate_differential_expression(df_late, df_normal, 'Late')\n",
    "\n",
    "    print(\"\\nâœ… Top 10 Genes with Log2FC > 1 or < -1 and P-Value < 0.05 (Late):\")\n",
    "    top10_late_significant_genes = late_results[late_results['Significant_Late'] == True] \\\n",
    "        .sort_values(by='P_Value_Late') \\\n",
    "        .head(100)\n",
    "    display(top10_late_significant_genes[['Gene', 'Log2_Fold_Change_Late', 'P_Value_Late']])\n",
    "\n",
    "    # ðŸ§¬ Combine Early + Late top 10 into a single list\n",
    "    top_genes_combined = list(\n",
    "        set(top10_early_significant_genes['Gene']).union(set(top10_late_significant_genes['Gene']))\n",
    "    )[:100]\n",
    "\n",
    "    print(f\"\\nðŸ” Final Combined Top 10 Genes from Early/Late Analyses:\\n{top_genes_combined}\")\n",
    "\n",
    "except Exception as e:\n",
    "    print(f\"âŒ Error: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "b4a98547",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: MYEOV\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for MYEOV:\n",
       "\n",
       "Okay, let's break down the information on the MYEOV gene and its role in cancer, focusing on the requested aspects.  It's important to note that research on MYEOV as a drug target is still relatively limited compared to more well-established cancer genes.\n",
       "\n",
       "**Gene: MYEOV (Myeloma Overexpressed)**\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "*   As of my knowledge cut-off date, there are **no FDA-approved drugs that directly target the MYEOV gene or its protein product.**  Research is ongoing to explore MYEOV as a potential therapeutic target, but it is mostly in preclinical or early clinical stages.\n",
       "\n",
       "    *   **Research focus:** Research is leaning more towards inhibiting MYEOV in cancer-related pathways.\n",
       "*   **Potential approaches under investigation (preclinical and early clinical):**\n",
       "\n",
       "    *   **Small molecule inhibitors:** Researchers are trying to identify or design small molecules that specifically bind to the MYEOV protein and inhibit its function.\n",
       "    *   **Antibody-based therapies:**  Antibodies could be developed to target the MYEOV protein on the surface of cancer cells, leading to cell death or immune-mediated destruction.\n",
       "    *   **RNA interference (RNAi) or antisense oligonucleotides (ASOs):** These approaches aim to reduce the expression of the MYEOV gene by targeting its mRNA.\n",
       "    *   **CRISPR-Cas9 gene editing:** While still largely in the research phase, CRISPR could theoretically be used to disrupt the MYEOV gene in cancer cells.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "*   **Since there are no approved drugs:** I can only describe *potential* interaction mechanisms:\n",
       "\n",
       "    *   **Small molecule inhibitors:**  These would likely bind to a specific active site or regulatory domain of the MYEOV protein, preventing it from interacting with its normal binding partners or carrying out its enzymatic activity.\n",
       "    *   **Antibody-based therapies:** Antibodies would bind to the MYEOV protein on the cell surface.  The antibody binding can trigger a few different mechanisms:\n",
       "        *   *Direct Inhibition:* The antibody physically blocks MYEOV from interacting with other proteins.\n",
       "        *   *Antibody-Dependent Cellular Cytotoxicity (ADCC):*  The antibody recruits immune cells (e.g., NK cells) to kill the cancer cell.\n",
       "        *   *Complement-Dependent Cytotoxicity (CDC):*  The antibody activates the complement system, leading to cancer cell lysis.\n",
       "        *   *Receptor-Mediated Internalization:*  The antibody binding causes the MYEOV protein (and the antibody) to be internalized into the cell, potentially disrupting its function.\n",
       "    *   **RNAi/ASOs:**  These molecules bind to the MYEOV mRNA, leading to its degradation or blocking its translation into protein.  This reduces the amount of MYEOV protein produced.\n",
       "    *   **CRISPR-Cas9:**  This system uses a guide RNA to direct the Cas9 enzyme to a specific location in the MYEOV gene.  Cas9 then cuts the DNA, disrupting the gene sequence.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "*   Again, these are *potential* mechanisms, given the lack of approved drugs:\n",
       "\n",
       "    *   **Small molecule inhibitors:** The mechanism would depend on the specific function of the MYEOV protein.  If MYEOV is an enzyme, the inhibitor might block the catalytic site.  If it's a scaffolding protein, the inhibitor might prevent protein-protein interactions.  The end result is a disruption of the MYEOV-related signaling pathway.\n",
       "    *   **Antibody-based therapies:**\n",
       "        *   *ADCC:* The antibody binds to MYEOV on the cancer cell.  The Fc region of the antibody binds to Fc receptors on immune cells (NK cells, macrophages).  This triggers the immune cell to release cytotoxic molecules that kill the cancer cell.\n",
       "        *   *CDC:* The antibody binds to MYEOV.  This activates the complement cascade, a series of protein activations that lead to the formation of a membrane attack complex (MAC) on the cancer cell surface, causing lysis.\n",
       "        *   *Receptor-Mediated Internalization:* The antibody-MYEOV complex is internalized into the cell via endocytosis. This can lead to degradation of MYEOV or disruption of its function within the cell.\n",
       "    *   **RNAi/ASOs:**  The RNAi or ASO molecule binds to the MYEOV mRNA.  This complex is then recognized by cellular machinery (e.g., the RISC complex for RNAi), leading to the degradation of the mRNA or blocking its translation by ribosomes.\n",
       "    *   **CRISPR-Cas9:**  The Cas9 enzyme, guided by the guide RNA, creates a double-stranded break in the MYEOV gene.  The cell attempts to repair this break, but the repair process is often error-prone, leading to mutations that disrupt the gene's function.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "*   The exact molecular function of MYEOV is not fully understood, and research is still ongoing. However, here's what is known:\n",
       "\n",
       "    *   **Overexpression in cancer:**  MYEOV is frequently overexpressed in various cancers, suggesting it plays a role in cancer development or progression.\n",
       "    *   **Role in cell cycle regulation:** Studies indicate MYEOV might be involved in regulating the cell cycle, particularly in the G1/S transition (the point where the cell commits to division).\n",
       "    *   **Interaction with other proteins:**  MYEOV is thought to interact with other proteins involved in cell signaling and proliferation.  Identifying these interaction partners is an active area of research.\n",
       "    *   **Potential involvement in DNA repair:** Some evidence suggests a potential link between MYEOV and DNA repair processes, although the specific mechanism is unclear.\n",
       "\n",
       "    In summary, MYEOV appears to be a protein involved in cell cycle control and potentially DNA repair, and its overexpression contributes to uncontrolled cell growth in cancer.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "*   Since there are no approved MYEOV-targeting therapies, this is a theoretical discussion.  If such therapies were developed, they would likely be combined with:\n",
       "\n",
       "    *   **Standard chemotherapy:** To enhance the effectiveness of chemotherapy by targeting cancer cells that are resistant or have escaped chemotherapy-induced cell death.\n",
       "    *   **Targeted therapies:** To synergize with other targeted therapies that inhibit different signaling pathways involved in cancer growth.\n",
       "    *   **Immunotherapies:** To improve the effectiveness of immunotherapies by making cancer cells more susceptible to immune attack.  For example, reducing MYEOV expression might increase the presentation of tumor-associated antigens on cancer cells, making them more visible to the immune system.\n",
       "    *   **Radiation therapy:** To sensitize cancer cells to radiation-induced damage.\n",
       "\n",
       "    The specific combination would depend on the type of cancer, the patient's profile, and the mechanism of action of the MYEOV-targeting therapy.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "*   Again, this is hypothetical:\n",
       "\n",
       "    *   **Early-stage cancer:**  In early-stage cancers, a MYEOV-targeting therapy might be used as an adjuvant treatment after surgery to prevent recurrence.\n",
       "    *   **Advanced-stage cancer:** In advanced-stage cancers, a MYEOV-targeting therapy might be used in combination with chemotherapy or other targeted therapies to slow disease progression and improve survival.\n",
       "    *   **Patient profile (biomarkers):**  Ideally, the use of a MYEOV-targeting therapy would be guided by biomarkers.  For example:\n",
       "        *   *MYEOV expression levels:* Patients with high MYEOV expression might be more likely to respond to the therapy.\n",
       "        *   *Mutations in MYEOV or related genes:* Certain mutations might predict sensitivity or resistance to the therapy.\n",
       "        *   *Genetic and Molecular Profiling:* Assessing the gene and protein expression of MYEOV can help identify the best treatments based on the patient's profile.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "*   MYEOV overexpression has been reported in several cancers, including:\n",
       "\n",
       "    *   **Multiple myeloma:** This is the cancer where it was originally identified (\"Myeloma Overexpressed\").\n",
       "    *   **Ovarian cancer:** High MYEOV expression has been linked to poor prognosis in ovarian cancer.\n",
       "    *   **Breast cancer:** MYEOV may play a role in breast cancer cell proliferation and metastasis.\n",
       "    *   **Lung cancer:** Some studies suggest MYEOV is overexpressed in certain subtypes of lung cancer.\n",
       "    *   **Other cancers:**  Expression has also been found in prostate, liver, colon, head and neck cancers, as well as lymphomas, but the extent and clinical significance vary.\n",
       "\n",
       "*   **Treatment options (excluding hypothetical MYEOV-targeted therapies):**  Standard treatments for these cancers depend on the specific type, stage, and patient characteristics:\n",
       "\n",
       "    *   **Multiple myeloma:** Chemotherapy, proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs (e.g., lenalidomide), stem cell transplantation, and monoclonal antibodies (e.g., daratumumab).\n",
       "    *   **Ovarian cancer:** Surgery, chemotherapy (platinum-based and taxanes), targeted therapies (e.g., PARP inhibitors), and immunotherapy.\n",
       "    *   **Breast cancer:** Surgery, radiation therapy, chemotherapy, hormone therapy (e.g., tamoxifen, aromatase inhibitors), and targeted therapies (e.g., trastuzumab for HER2-positive breast cancer).\n",
       "    *   **Lung cancer:** Surgery, radiation therapy, chemotherapy, targeted therapies (e.g., EGFR inhibitors, ALK inhibitors), and immunotherapy (e.g., PD-1/PD-L1 inhibitors).\n",
       "\n",
       "**Important Considerations:**\n",
       "\n",
       "*   **Research is evolving:** Our understanding of MYEOV's function and its role in cancer is still developing.  New research findings could change the information presented here.\n",
       "*   **Clinical trials:** The most promising avenue for accessing MYEOV-targeted therapies, if they become available, would be through clinical trials.\n",
       "\n",
       "In conclusion, while MYEOV is an interesting target in cancer research, there are currently no approved drugs that specifically target it. Future research and clinical trials will determine whether MYEOV-targeted therapies can become a valuable addition to cancer treatment.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: C13orf36\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for C13orf36:\n",
       "\n",
       "Let's investigate the gene C13orf36.  It's important to note that C13orf36 is a gene with limited known information.  Answers here are based on current, publicly available data and may change as research progresses.  Finding direct drug targets for genes with unknown function is rare, so the information below will likely be limited.\n",
       "\n",
       "**Gene: C13orf36** (Chromosome 13 open reading frame 36)\n",
       "\n",
       "Based on current research, there's limited information available about C13orf36. It is predicted to be a protein-coding gene.  Therefore, the answers to your questions will be incomplete due to this lack of information.\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "*   **Likely None Directly Known:** As of the current available information, there are **no major, well-established drugs that directly target C13orf36** or its protein product. This is primarily because the protein's function and structure are poorly understood.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "*   **Not Applicable:** Because there are no known direct drug targets, this question cannot be answered.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "*   **Not Applicable:**  Since no direct drug interactions are known, there are no biological mechanisms to describe.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "*   **Poorly Defined:**  The molecular function of C13orf36 is **largely unknown**. Prediction algorithms suggest it's a protein-coding gene, meaning it is transcribed into mRNA which is then translated into a protein. Beyond that, its specific role is unclear. Computational analyses might suggest potential involvement in certain cellular processes based on sequence homology to other proteins, but these are speculative without experimental validation. Research might suggest a possible role in cell growth or differentiation, but experimental evidence is needed.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "*   **Not Applicable:** Because no therapies specifically target C13orf36, there are no combination therapies to discuss.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "*   **Not Applicable:** Because no therapies specifically target C13orf36, there are no stage- or patient-profile variations to discuss.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "*   **Potential Associations, but No Targeted Therapies:** Some studies may show correlations between C13orf36 expression levels and certain cancers. However, correlation does not equal causation.  Even if C13orf36 expression is altered in a particular cancer, it doesn't mean it's a driver of the disease or a suitable drug target.\n",
       "\n",
       "*   **General Cancer Treatment Options Apply:** If C13orf36 expression is found to be associated with a particular cancer, the patient would be treated with standard-of-care therapies for that cancer type based on its stage, grade, and other relevant biomarkers.  These therapies could include:\n",
       "    *   Surgery\n",
       "    *   Radiation therapy\n",
       "    *   Chemotherapy\n",
       "    *   Targeted therapies (targeting other well-established cancer drivers)\n",
       "    *   Immunotherapy\n",
       "\n",
       "**Important Considerations:**\n",
       "\n",
       "*   **Research is Ongoing:** Scientific knowledge is constantly evolving.  It's possible that future research will uncover more information about C13orf36's function, its role in disease, and potential therapeutic targets.\n",
       "*   **Bioinformatics and Functional Genomics:** Researchers might use techniques like gene knockout/knockdown (e.g., using CRISPR or RNA interference) to study the effects of C13orf36 manipulation in cell lines or animal models. These experiments could provide clues about its function.\n",
       "*   **Expression Profiling:** Analyzing C13orf36 mRNA or protein expression levels in different tissues and disease states could reveal potential links to specific cancers or other disorders.\n",
       "*   **Pathway Analysis:** Computational methods can be used to predict the pathways in which C13orf36 might be involved, based on its sequence and predicted structure.\n",
       "\n",
       "**In summary, while C13orf36 is a gene of interest, its function and role in disease are currently poorly understood.  Therefore, there are no known drugs that directly target it, and its involvement in cancer treatment is indirect at best (through its potential association with certain cancers treated with standard-of-care therapies). Future research is needed to elucidate its biological role and therapeutic potential.**\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: PTPRQ\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for PTPRQ:\n",
       "\n",
       "Okay, let's break down the information about the PTPRQ gene and its potential relevance to cancer therapeutics.  It's important to note that PTPRQ is not a *major* drug target in cancer right now like EGFR or HER2.  Research is still ongoing, and drugs directly targeting it are not widely used clinically. However, we can discuss potential and experimental strategies.\n",
       "\n",
       "**Gene: PTPRQ (Protein Tyrosine Phosphatase Receptor Type Q)**\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "*   Currently, there are *no* major, clinically approved drugs that directly target PTPRQ for cancer treatment.  Research is in early stages, but there are studies on antibodies and small molecule inhibitors.\n",
       "*   **Potential Drug Targets (Experimental):**\n",
       "    *   **Antibodies:**  These would bind to the extracellular domain of the PTPRQ protein.\n",
       "    *   **Small Molecule Inhibitors:**  These would attempt to block the catalytic activity of the phosphatase domain inside the cell.\n",
       "    *   **PROTACs (Proteolysis-Targeting Chimeras):** These are a newer technology that could be used to target the PTPRQ protein for degradation.\n",
       "    *   **Gene Therapy / Gene Editing:**  Potentially to restore normal function of the gene if it's been silenced or mutated in cancer cells.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "*   **Antibodies:**  Bind specifically to the PTPRQ protein on the cell surface.\n",
       "*   **Small Molecule Inhibitors:** Bind to the catalytic domain of the PTPRQ protein, interfering with its phosphatase activity.\n",
       "*   **PROTACs:** Bind to the PTPRQ protein and an E3 ubiquitin ligase, leading to ubiquitination and degradation of PTPRQ.\n",
       "*   **Gene Therapy/Gene Editing:**  Modifies the DNA sequence of the PTPRQ gene itself, aiming to restore its expression or correct mutations.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "*   **Antibodies:**\n",
       "    *   **Receptor Blocking:**  The antibody physically blocks the PTPRQ protein from interacting with its natural ligands or substrates.  This can disrupt downstream signaling pathways.\n",
       "    *   **Internalization/Degradation:**  Antibody binding can trigger the cell to internalize the PTPRQ protein, leading to its degradation.\n",
       "    *   **ADCC (Antibody-Dependent Cell-mediated Cytotoxicity):** The antibody binds to PTPRQ on cancer cells, marking them for destruction by immune cells (e.g., NK cells).\n",
       "    *   **CDC (Complement-Dependent Cytotoxicity):** The antibody activates the complement system, leading to direct lysis (rupture) of the cancer cell.\n",
       "*   **Small Molecule Inhibitors:**\n",
       "    *   **Competitive Inhibition:**  The inhibitor binds to the active site of the PTPRQ phosphatase domain, preventing the natural substrate (a phosphorylated protein) from binding and being dephosphorylated.\n",
       "    *   **Allosteric Inhibition:** The inhibitor binds to a site on the PTPRQ protein *other* than the active site, causing a conformational change that reduces or eliminates the protein's activity.\n",
       "*   **PROTACs:**\n",
       "    *   PROTACs recruit an E3 ubiquitin ligase to the target protein (PTPRQ). The E3 ligase then attaches ubiquitin to the PTPRQ, marking it for degradation by the proteasome.\n",
       "*   **Gene Therapy/Gene Editing:**\n",
       "    *   **Gene Therapy:** Delivers a functional copy of the PTPRQ gene into the cancer cell, allowing it to produce normal PTPRQ protein.\n",
       "    *   **Gene Editing (e.g., CRISPR):**  Uses enzymes to precisely cut and repair the DNA at the PTPRQ locus, correcting mutations or restoring proper gene expression.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "*   PTPRQ encodes a **protein tyrosine phosphatase receptor type Q**.\n",
       "*   **Molecular Function:**  It's an enzyme (a phosphatase) that removes phosphate groups from tyrosine residues on other proteins.  This is a critical regulatory mechanism that controls the activity of many signaling pathways within cells.\n",
       "*   **Cellular Role:** PTPRQ is involved in a variety of cellular processes, including cell growth, differentiation, adhesion, and signal transduction.\n",
       "*   **Important Note:** PTPRQ is highly expressed in inner ear hair cells, kidney and neuronal tissues, and it plays an essential role in hearing, kidney and neuronal function.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "*   Since PTPRQ-targeted therapies are not yet standard, combinations are theoretical and based on preclinical research.\n",
       "*   **Potential Combinations:**\n",
       "    *   **With Chemotherapy:** To enhance the effectiveness of chemotherapy by sensitizing cancer cells to its effects.\n",
       "    *   **With Immunotherapy:** To boost the immune system's ability to recognize and destroy cancer cells.\n",
       "    *   **With Targeted Therapies:**  To block multiple signaling pathways simultaneously, preventing cancer cells from adapting and becoming resistant.\n",
       "    *   **With Radiation Therapy:**  To increase the sensitivity of cancer cells to radiation.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "*   Again, since these are experimental therapies, there are no established guidelines.  However, principles would likely be similar to other targeted therapies:\n",
       "*   **Cancer Stage:**\n",
       "    *   **Early Stage:**  PTPRQ-targeted therapy *might* be considered as an adjuvant treatment after surgery to prevent recurrence, especially if the cancer has a specific PTPRQ alteration.\n",
       "    *   **Advanced/Metastatic Stage:** PTPRQ-targeted therapy might be used as a single agent or in combination with other therapies to shrink tumors, slow disease progression, and improve quality of life.\n",
       "*   **Patient Profile:**\n",
       "    *   **Genetic Testing:**  Crucially, patients would need to be tested for alterations in the PTPRQ gene or the pathways it regulates.  Therapies would likely be most effective in patients whose cancers have specific PTPRQ mutations or dysregulation that make them sensitive to PTPRQ inhibition or modulation.\n",
       "    *   **Comorbidities:**  Patient's overall health and other medical conditions would need to be considered to minimize side effects.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "*   **Cancers Associated:**\n",
       "    *   The role of PTPRQ in cancer is still being investigated, and its association with specific cancers is not fully established.  However, research suggests potential roles in:\n",
       "        *   **Lung Cancer:** Some studies have implicated PTPRQ in the development and progression of lung cancer.\n",
       "        *   **Breast Cancer:** Alterations in PTPRQ have been observed in some breast cancer subtypes.\n",
       "        *   **Renal Cell Carcinoma:** PTPRQ may play a role in the development and progression of kidney cancer.\n",
       "        *   **Other Cancers:**  Research is ongoing to explore its involvement in other cancer types.\n",
       "*   **Treatment Options:**\n",
       "    *   Currently, standard treatment options for these cancers *do not* specifically target PTPRQ.  Treatment depends on the type and stage of cancer, and may include:\n",
       "        *   Surgery\n",
       "        *   Chemotherapy\n",
       "        *   Radiation Therapy\n",
       "        *   Targeted Therapies (that target other genes/proteins)\n",
       "        *   Immunotherapy\n",
       "        *   Clinical Trials (testing novel PTPRQ-targeted therapies)\n",
       "\n",
       "**In Summary:**\n",
       "\n",
       "While PTPRQ is an interesting target, it's important to understand that drugs directly targeting it for cancer treatment are not yet a standard part of care. Research is ongoing, and future clinical trials will be necessary to determine the safety and efficacy of PTPRQ-targeted therapies.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: BCL2L10\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for BCL2L10:\n",
       "\n",
       "Okay, let's break down BCL2L10 and its role in cancer, focusing on your specific questions.  It's important to note that BCL2L10 is still a relatively understudied member of the BCL2 family, and therefore, there are fewer established drugs and clinical applications compared to its better-known relatives like BCL2 and BCL-XL.\n",
       "\n",
       "**Gene: BCL2L10**\n",
       "\n",
       "1.  **What are the major drugs that target this gene?**\n",
       "\n",
       "    Currently, there are no *major* drugs specifically designed and approved to target BCL2L10 directly.  This is a key distinction.  While some drugs may have an *indirect* effect, there aren't any highly selective BCL2L10 inhibitors in clinical use. The main approach is to target other BCL2 family proteins, which can indirectly influence BCL2L10.\n",
       "\n",
       "    *   **BCL2 Inhibitors (e.g., Venetoclax):** These drugs target BCL2. Although they don't directly hit BCL2L10, the balance within the BCL2 family can shift, potentially affecting the apoptotic threshold in cells where BCL2L10 is also present.\n",
       "\n",
       "    *   **BCL-XL Inhibitors (e.g., Navitoclax):**  Similar to BCL2 inhibitors, these target a different member of the family.  Navitoclax was one of the first BCL-2 family inhibitors developed and showed promise, but its significant thrombocytopenic (low platelet) toxicity limited its widespread use. Newer BCL-XL inhibitors are in development with improved safety profiles.\n",
       "\n",
       "2.  **How does each drug interact with the gene or protein product?**\n",
       "\n",
       "    *   **BCL2/BCL-XL Inhibitors:** These drugs bind directly to the BH3 domain-binding groove of the BCL2 or BCL-XL protein. They are small molecules that mimic the BH3 domain of pro-apoptotic proteins.\n",
       "\n",
       "3.  **What's the biological mechanism of each interaction?**\n",
       "\n",
       "    *   **BCL2/BCL-XL Inhibitors:**  The BCL2 family of proteins regulates apoptosis (programmed cell death).  Anti-apoptotic members like BCL2 and BCL-XL prevent apoptosis by binding to and sequestering pro-apoptotic proteins (e.g., BAX, BAK, BIM, BID) at the mitochondrial membrane.  This prevents the formation of pores in the mitochondrial outer membrane, which would release cytochrome c and trigger the caspase cascade, leading to cell death.  Inhibitors like venetoclax and navitoclax bind to BCL2 or BCL-XL, displacing the pro-apoptotic proteins.  This frees the pro-apoptotic proteins to oligomerize, form pores, release cytochrome c, and activate the caspase cascade, leading to apoptosis.\n",
       "        *   In essence, these inhibitors \"unleash\" the cell's natural self-destruction mechanisms.\n",
       "\n",
       "4.  **What is the gene's molecular function?**\n",
       "\n",
       "    BCL2L10 (BCL2-like protein 10), also known as Boo, is a member of the BCL2 family of apoptosis regulators.  Its precise function is still being elucidated, but here's what's generally understood:\n",
       "\n",
       "    *   **Anti-Apoptotic:** BCL2L10 is generally considered an anti-apoptotic protein.  It functions to inhibit programmed cell death (apoptosis).\n",
       "    *   **Mitochondrial Localization:** Like other BCL2 family members, BCL2L10 localizes to the outer mitochondrial membrane.\n",
       "    *   **Interaction with other BCL2 proteins:** It can interact with other BCL2 family members, modulating their activity. It has been reported to bind to both pro-apoptotic (e.g., Bim) and anti-apoptotic (e.g., Bcl-XL) proteins. The outcome of these interactions (pro- or anti-apoptotic) depends on the cellular context and the relative levels of the various BCL2 family members.\n",
       "    *   **Regulation of mitochondrial dynamics and metabolism:**  Emerging evidence suggests BCL2L10 can play a role in mitochondrial dynamics, including fusion and fission, and in regulating mitochondrial metabolism.\n",
       "    *   **Role in Reproduction:**  BCL2L10 plays an important role in female fertility, especially in oocyte development and function, and in preventing apoptosis in developing germ cells.\n",
       "\n",
       "5.  **How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "    Because there are no therapies directly targeting BCL2L10, combination strategies center on using drugs that target other BCL2 family members.  Here's the general idea:\n",
       "\n",
       "    *   **BCL2 Inhibitors + Chemotherapy/Other Targeted Therapies:**  Venetoclax (a BCL2 inhibitor) is often combined with chemotherapy (e.g., hypomethylating agents like azacitidine or decitabine, or with low-dose cytarabine) in hematological malignancies like acute myeloid leukemia (AML).  It's also used in combination with anti-CD20 antibodies (e.g., rituximab or obinutuzumab) in chronic lymphocytic leukemia (CLL). The rationale is that the BCL2 inhibitor sensitizes cancer cells to the cytotoxic effects of chemotherapy or other targeted agents.\n",
       "    *   **BCL-XL Inhibitors + Other Therapies:**  Due to toxicity concerns with older BCL-XL inhibitors like Navitoclax, combinations were limited.  Newer BCL-XL inhibitors with improved safety profiles are being explored in combination with other targeted therapies, particularly in solid tumors.\n",
       "    *   **Rationale for Combinations:** Cancer cells often rely on multiple anti-apoptotic mechanisms. By inhibiting one pathway (e.g., BCL2), you might reveal a dependence on another (e.g., BCL-XL).  Combination therapy aims to overcome this resistance by simultaneously targeting multiple survival pathways.\n",
       "\n",
       "6.  **How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "    *   **Cancer Stage:**\n",
       "        *   **Early Stage:** In some early-stage hematological malignancies (e.g., CLL with specific favorable prognostic markers), a \"watch and wait\" approach might be initially adopted. Treatment with BCL2 inhibitors may be reserved for later stages with more aggressive disease.\n",
       "        *   **Advanced/Relapsed/Refractory:** BCL2 inhibitors are frequently used in advanced, relapsed, or refractory hematological malignancies, especially when other treatment options have been exhausted.\n",
       "    *   **Patient Profile:**\n",
       "        *   **Age and Comorbidities:**  Older patients or those with significant comorbidities may not be able to tolerate intensive chemotherapy regimens. BCL2 inhibitors, often in combination with less intensive therapies, can be a valuable option for these patients.\n",
       "        *   **Genetic Mutations:**  Certain genetic mutations can predict response or resistance to BCL2 inhibitors.  For example, in AML, TP53 mutations can influence the efficacy of venetoclax-based regimens.\n",
       "        *   **Prior Therapies:**  Prior exposure to certain chemotherapy agents or targeted therapies can influence the choice of subsequent treatment, including the use of BCL2 inhibitors.\n",
       "        *   **Platelet Count:** Because Navitoclax can cause thrombocytopenia, it's usage is more challenging in patients who have low platelets to begin with. Newer BCL-XL inhibitors are being designed to minimize this side effect.\n",
       "\n",
       "7.  **What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "    *   **Cancers Associated with BCL2L10:** BCL2L10 dysregulation (e.g., overexpression) has been implicated in various cancers, including:\n",
       "\n",
       "        *   **Hematological Malignancies:** Leukemia (AML, ALL, CLL), lymphoma (including diffuse large B-cell lymphoma [DLBCL]), and multiple myeloma.\n",
       "        *   **Solid Tumors:** Ovarian cancer, breast cancer, lung cancer, gastric cancer, and melanoma. However, the precise role and frequency of BCL2L10 dysregulation vary across these cancer types. The evidence for its specific role in these cancers is generally less strong than for BCL2 or BCL-XL.\n",
       "        *   **Cancer Stem Cells:** Increased BCL2L10 expression has also been linked to cancer stem cell (CSC) maintenance in various cancers.\n",
       "    *   **Treatment Options:**\n",
       "        *   **Hematological Malignancies:**\n",
       "            *   **AML:** Venetoclax + azacitidine or decitabine; venetoclax + low-dose cytarabine; intensive chemotherapy (depending on patient fitness); stem cell transplantation.\n",
       "            *   **CLL:** Venetoclax + obinutuzumab or rituximab; chemoimmunotherapy (FCR, BR); targeted therapies (BTK inhibitors, PI3K inhibitors).\n",
       "        *   **Solid Tumors:**  Treatment options depend heavily on the specific cancer type, stage, and patient characteristics. Chemotherapy, radiation therapy, surgery, targeted therapies (e.g., EGFR inhibitors, HER2 inhibitors), and immunotherapy are all potential options. *However, it's crucial to reiterate that there are currently no approved therapies that directly target BCL2L10 in solid tumors.* BCL2 or BCL-XL inhibitors are being explored in clinical trials in some solid tumors, but they are not yet standard of care.\n",
       "\n",
       "**Important Considerations:**\n",
       "\n",
       "*   **Research is Ongoing:** The role of BCL2L10 in cancer is still being actively investigated.  New research may reveal more specific roles for this protein and potentially lead to the development of more targeted therapies in the future.\n",
       "*   **Context-Dependent Effects:**  The function of BCL2L10 can be context-dependent, meaning its effects can vary depending on the specific cancer type, the presence of other mutations, and the cellular environment.\n",
       "*   **BH3 Mimetics and Drug Development:** Pharmaceutical companies are actively developing new generations of BH3 mimetics with improved selectivity and safety profiles.  These agents may eventually prove to be valuable in targeting BCL2L10 or other BCL2 family members in cancer therapy.\n",
       "*   **Personalized Medicine:** As we gain a better understanding of the molecular mechanisms driving cancer, treatment strategies are becoming increasingly personalized.  This includes considering the expression levels of BCL2L10 and other BCL2 family members when making treatment decisions.\n",
       "*   **Role in resistance:** BCL2L10 has been reported to contribute to drug resistance in certain cancers, including resistance to chemotherapy and targeted therapies.\n",
       "\n",
       "This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: ZYG11A\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for ZYG11A:\n",
       "\n",
       "Let's break down ZYG11A and address your questions based on currently available scientific information.\n",
       "\n",
       "**Important Note:**  ZYG11A is not a well-established drug target like some other cancer genes (e.g., EGFR, HER2). Therefore, there are **no major drugs that directly target ZYG11A specifically** in clinical use. Research into its role in cancer is ongoing, but directly drugging it is not a common therapeutic strategy *yet*. The following information provides background on the gene itself and discusses general concepts related to targeting gene products in cancer.\n",
       "\n",
       "**Gene: ZYG11A**\n",
       "\n",
       "*   **Full Name:** Zinc finger protein ZYG11A\n",
       "*   **Location:** Human chromosome 1p36.11\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "*   **Answer:**  As stated above, there are **no major drugs currently in clinical use that directly target ZYG11A.** Research is ongoing, and potential indirect impacts may exist (see below).\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "*   **Answer:** Since there are no specific drugs, this question is not applicable. However, it is important to recognize that research into gene expression regulation and protein-protein interactions is often conducted to establish that a particular gene is a suitable target.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "*   **Answer:** Not applicable due to the lack of drugs targeting ZYG11A.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "*   **Answer:**  ZYG11A is a zinc finger protein. Zinc finger proteins are a large family of proteins involved in a wide variety of cellular processes, including:\n",
       "\n",
       "    *   **Transcription Regulation:**  ZYG11A is known to function as a **transcriptional repressor**.  It binds to DNA and can suppress the expression of specific genes.\n",
       "    *   **Cell Cycle Regulation:** ZYG11A interacts with other proteins involved in cell cycle control, particularly the **MDM2-p53 pathway**.  MDM2 is an E3 ubiquitin ligase that targets the tumor suppressor p53 for degradation.  ZYG11A can bind to MDM2 and influence its activity, indirectly affecting p53 levels.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "*   **Answer:** Because there are no direct therapies, this is a theoretical discussion.  If ZYG11A were a therapeutic target, potential combination strategies might consider:\n",
       "\n",
       "    *   **Targeting p53 Pathway:**  If ZYG11A is found to consistently suppress p53, therapies that activate p53 (e.g., MDM2 inhibitors) could be used in combination with treatments that modulate ZYG11A expression.\n",
       "    *   **Combining with Standard Therapies:**  Any ZYG11A-related therapy would likely be tested in combination with standard chemotherapy, radiation, or targeted therapies relevant to the specific cancer type.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "*   **Answer:**  Hypothetically, if a ZYG11A-based therapy existed:\n",
       "\n",
       "    *   **Stage:** In early-stage cancers, strategies aimed at preventing recurrence by targeting ZYG11A might be considered. In advanced stages, the focus would likely be on slowing tumor growth and improving survival, potentially using ZYG11A-targeted therapies in combination with other treatments.\n",
       "    *   **Patient Profile:**\n",
       "        *   **p53 Status:** Since ZYG11A interacts with the p53 pathway, a patient's p53 status (mutated or wild-type) could influence the effectiveness of ZYG11A-related therapies.  If ZYG11A suppresses p53, it may be more effective to target ZYG11A in patients with wild-type p53.\n",
       "        *   **Expression Levels:** The level of ZYG11A expression in a patient's tumor could be a biomarker to predict response to therapy.\n",
       "        *   **Genetic Background:**  Genetic variations in ZYG11A or related genes could affect treatment response.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "*   **Cancers Associated:**  ZYG11A has been implicated in various cancers, but its role is not always well-defined and can be context-dependent. Studies have linked it to:\n",
       "\n",
       "    *   **Breast Cancer:** Some studies suggest that ZYG11A may be involved in the development and progression of breast cancer.\n",
       "    *   **Lung Cancer:** Dysregulation of ZYG11A has also been observed in lung cancer.\n",
       "    *   **Other Cancers:** ZYG11A is also linked to other cancers, including: prostate cancer, colorectal cancer, and esophageal cancer.\n",
       "\n",
       "*   **Treatment Options:**  Because there are no specific drugs directly targeting ZYG11A, the treatment options are those standard for the specific cancer type and stage.  Examples include:\n",
       "\n",
       "    *   **Surgery:** Removal of the tumor.\n",
       "    *   **Chemotherapy:** Using drugs to kill cancer cells.\n",
       "    *   **Radiation Therapy:** Using high-energy rays to kill cancer cells.\n",
       "    *   **Targeted Therapy:** Using drugs that target specific molecules involved in cancer cell growth and survival. (This could theoretically include drugs targeting downstream targets of ZYG11A if those are identified).\n",
       "    *   **Immunotherapy:** Using the body's immune system to fight cancer.\n",
       "    *   **Hormone Therapy:**  For hormone-sensitive cancers (e.g., some breast and prostate cancers).\n",
       "\n",
       "**Summary and Future Directions:**\n",
       "\n",
       "ZYG11A is a zinc finger protein with a role in transcriptional repression and cell cycle regulation, particularly through its interaction with the MDM2-p53 pathway. While it has been implicated in various cancers, it is *not currently a direct drug target*.  Future research will likely focus on:\n",
       "\n",
       "*   **Understanding the precise role of ZYG11A in different cancer types.**\n",
       "*   **Identifying specific genes that ZYG11A regulates and their role in cancer development.**\n",
       "*   **Exploring whether targeting ZYG11A indirectly (e.g., by modulating its expression or disrupting its interactions with other proteins) could be a viable therapeutic strategy.**\n",
       "*   **Identifying biomarkers related to ZYG11A expression or activity that could predict response to therapy.**\n",
       "\n",
       "Keep in mind that scientific knowledge is constantly evolving.  Consult with medical professionals and refer to the latest research for the most up-to-date information.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: EPYC\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for EPYC:\n",
       "\n",
       "Okay, let's break down the information regarding the EPYC gene and its relationship to cancer and potential treatments.  Keep in mind that my information is based on publicly available knowledge and might not include the most cutting-edge, unpublished research.  **Also, I am an AI and cannot provide medical advice. Always consult with a qualified healthcare professional for any health concerns or treatment decisions.**\n",
       "\n",
       "**1. What are the major drugs that target this gene (EPYC)?**\n",
       "\n",
       "Unfortunately, there are **no currently approved drugs that *directly* target the EPYC gene or its protein product**.  This is a critical point. EPYC is a relatively newly characterized gene, and drug development targeting it is still in early stages.\n",
       "\n",
       "**Why is this the case?**\n",
       "\n",
       "*   **Novel Target:** EPYC is a relatively recent discovery in cancer research. Drug development takes significant time and resources.\n",
       "*   **Mechanism Elucidation:** The precise role of EPYC in cancer development is still being investigated. Before designing a drug, scientists need to understand *how* EPYC contributes to the disease.\n",
       "*   **Target Validation:** Researchers need to validate that targeting EPYC will have a therapeutic effect without causing unacceptable side effects.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "Given that there are no approved drugs directly targeting EPYC, this question is currently unanswerable for approved therapeutics.  However, there might be *research tools* or *investigational compounds* being used in laboratory settings that could interact with EPYC.  These would likely be things like:\n",
       "\n",
       "*   **siRNAs or shRNAs:**  These are short RNA molecules designed to silence the EPYC gene by targeting its mRNA, preventing the protein from being produced. This is a gene knockdown approach for research purposes.\n",
       "*   **Antibodies:** Antibodies could be developed to bind to the EPYC protein.  These could be used to block its interaction with other proteins, mark it for degradation, or deliver a cytotoxic payload to cells expressing EPYC.\n",
       "*   **Small molecule inhibitors:** Small molecules could be designed to interfere with the EPYC protein's function, such as blocking its active site or preventing it from interacting with its binding partners.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "Since there are no approved drugs, this is also speculative based on potential research tools:\n",
       "\n",
       "*   **siRNA/shRNA:** The siRNA or shRNA is designed to be complementary to a specific sequence of EPYC mRNA.  Once inside the cell, it binds to the mRNA, triggering its degradation by cellular enzymes or preventing its translation into protein.\n",
       "*   **Antibody:** The antibody binds to a specific epitope (a specific region) on the EPYC protein.  The mechanism of action depends on the antibody's design:\n",
       "    *   **Neutralizing antibody:** Blocks the EPYC protein from interacting with its normal binding partners, disrupting its function.\n",
       "    *   **Antibody-dependent cell-mediated cytotoxicity (ADCC):** The antibody binds to EPYC on the cancer cell surface, then recruits immune cells (e.g., NK cells) to kill the cancer cell.\n",
       "    *   **Complement-dependent cytotoxicity (CDC):** The antibody activates the complement system, leading to lysis (destruction) of the cancer cell.\n",
       "    *   **Antibody-drug conjugate (ADC):** The antibody is linked to a cytotoxic drug.  The antibody delivers the drug specifically to cancer cells expressing EPYC.\n",
       "*   **Small Molecule Inhibitor:** The small molecule binds to the EPYC protein, typically within a binding pocket or active site.  This binding alters the protein's conformation or blocks access to its substrates or binding partners, thereby inhibiting its function.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "Based on the available research, the EPYC gene encodes a protein that plays a role in the **endoplasmic reticulum (ER)-mitochondria encounter structure (ERMES)**. ERMES is a complex of proteins that physically tethers the ER and mitochondria, facilitating communication and the transfer of lipids between these two organelles.\n",
       "\n",
       "*   **Lipid Metabolism:**  EPYC likely plays a role in lipid transport and metabolism within the ER-mitochondria network. This is particularly important in cancer cells, which often have altered lipid metabolism to support their rapid growth and proliferation.\n",
       "*   **Calcium Homeostasis:** The ER and mitochondria are key regulators of calcium signaling. EPYC may influence calcium flux between these organelles, affecting cell survival and apoptosis (programmed cell death).\n",
       "*   **Mitochondrial Function:** By modulating lipid composition and calcium levels, EPYC might influence mitochondrial function, including ATP production (energy) and reactive oxygen species (ROS) generation.\n",
       "*   **Cellular Stress Response:** Dysregulation of ER-mitochondria communication can lead to cellular stress. EPYC may be involved in the cell's response to ER stress, unfolded protein response (UPR), and other forms of stress.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "Since there are no direct EPYC-targeted therapies currently, this question is speculative. However, if such therapies were developed, they might be combined with:\n",
       "\n",
       "*   **Standard Chemotherapy:** To enhance the effectiveness of chemotherapy by targeting cancer cells with dysregulated EPYC function.\n",
       "*   **Targeted Therapies:** To synergistically target multiple pathways involved in cancer growth and survival.\n",
       "*   **Immunotherapy:** To enhance the anti-tumor immune response by modulating EPYC-related cellular processes that influence immune cell activity.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "Again, this is speculative without approved EPYC-targeted therapies. But in general, cancer treatments are often tailored based on:\n",
       "\n",
       "*   **Cancer Stage:** Early-stage cancers might be treated with surgery, radiation, or targeted therapies. Advanced-stage cancers often require a combination of treatments, including chemotherapy, immunotherapy, and potentially EPYC-targeted therapies if they become available.\n",
       "*   **Patient Profile:**\n",
       "    *   **Genetic Mutations:** The presence of other mutations in genes related to EPYC function might influence treatment decisions.\n",
       "    *   **Overall Health:** The patient's general health and ability to tolerate aggressive treatments are considered.\n",
       "    *   **Age:** Age can influence treatment choices and dosages.\n",
       "    *   **Comorbidities:** Pre-existing medical conditions can affect treatment options.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "Several studies have suggested potential associations of EPYC with different types of cancers, including:\n",
       "\n",
       "*   **Lung Cancer**\n",
       "*   **Breast Cancer**\n",
       "*   **Colorectal Cancer**\n",
       "*   **Ovarian Cancer**\n",
       "*   **Gliomas**\n",
       "\n",
       "**Important Note:** While EPYC expression or mutations might be associated with these cancers, it doesn't necessarily mean it's a *driver* of the cancer or a validated therapeutic target *yet*. More research is needed.\n",
       "\n",
       "**Treatment Options (General for those cancers - not EPYC specific):**\n",
       "\n",
       "The treatment options for these cancers vary widely depending on the stage, grade, and specific characteristics of the tumor, as well as the patient's overall health. Standard treatments typically include:\n",
       "\n",
       "*   **Surgery:** To remove the tumor.\n",
       "*   **Radiation Therapy:** To kill cancer cells with high-energy rays.\n",
       "*   **Chemotherapy:** To kill cancer cells with drugs.\n",
       "*   **Targeted Therapy:** To target specific molecules or pathways involved in cancer growth.\n",
       "*   **Immunotherapy:** To stimulate the immune system to attack cancer cells.\n",
       "*   **Hormone Therapy:** For hormone-sensitive cancers like breast and prostate cancer.\n",
       "\n",
       "**In conclusion:**\n",
       "\n",
       "EPYC is an emerging area of cancer research. While it holds promise as a potential therapeutic target, there are currently no approved drugs that directly target the EPYC gene or its protein product. Research is ongoing to better understand its role in cancer and to develop targeted therapies. Always consult with a qualified healthcare professional for diagnosis and treatment decisions related to cancer.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: DVWA\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for DVWA:\n",
       "\n",
       "Okay, let's break down the information about the DVWA gene and address your questions.  It's important to note that DVWA is a relatively understudied gene, so the information available is less extensive than for some other well-known cancer-related genes.\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "As of my knowledge cutoff date (September 2021), there are **no known drugs specifically designed to directly target the DVWA gene or its protein product**.  This is likely because its exact role and importance in cancer progression are still being actively researched.  It doesn't have a well-defined druggable pocket or enzymatic activity that would lend itself easily to small molecule inhibition, for example.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "Since there are no drugs directly targeting DVWA, this question is not applicable.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "N/A\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "The DVWA gene encodes a protein of unknown function. It has been shown to act as a transcriptional repressor in several types of cancer. It is highly conserved across many species.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "Because there are no direct therapies targeting DVWA, this question is also difficult to answer definitively.  If DVWA is found to play a crucial role in a specific signaling pathway or cellular process, researchers *might* explore combination therapies that target that pathway in conjunction with other standard cancer treatments.  However, this would be based on an indirect effect of influencing DVWA activity, not a direct targeting of the gene or protein.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "As DVWA is not a direct drug target, treatments do not currently vary based on DVWA status. Treatment decisions are based on standard factors like:\n",
       "\n",
       "*   **Cancer Type:** The specific type of cancer is the primary driver of treatment choices.\n",
       "*   **Stage:** The stage of the cancer (how far it has spread) significantly impacts treatment intensity and approach.\n",
       "*   **Patient Health:** Overall health, age, and other medical conditions influence treatment options and potential side effects.\n",
       "*   **Genetic/Molecular Markers:**  Other genetic mutations or molecular markers (e.g., EGFR, KRAS, HER2) in the cancer cells are often used to guide targeted therapies.\n",
       "*   **Performance Status:**  A measure of a patient's ability to perform daily activities, which helps determine their tolerance for aggressive treatments.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "DVWA has been implicated in several cancers, although its exact role and the strength of the association vary:\n",
       "\n",
       "*   **Colorectal Cancer:** Some studies have shown altered DVWA expression in colorectal cancer. Standard treatments for colorectal cancer include surgery, chemotherapy (e.g., FOLFOX, FOLFIRI), radiation therapy, and targeted therapies (e.g., anti-EGFR antibodies like cetuximab or panitumumab for KRAS wild-type tumors, anti-VEGF antibodies like bevacizumab).\n",
       "*   **Prostate Cancer:** Research suggests a potential role for DVWA in prostate cancer development. Treatment options for prostate cancer include active surveillance, surgery (prostatectomy), radiation therapy, hormone therapy (androgen deprivation therapy), chemotherapy, and immunotherapy (e.g., sipuleucel-T).\n",
       "*   **Other Cancers:** Some studies have suggested involvement in other cancers as well. Treatment options would depend on the specific cancer type.\n",
       "\n",
       "**Important Considerations and Future Research:**\n",
       "\n",
       "*   **Ongoing Research:** Research on DVWA is ongoing.  As our understanding of its function and role in cancer progresses, it's possible that new therapeutic strategies may emerge.\n",
       "*   **Indirect Targeting:** Even if direct drugs targeting DVWA are not developed, researchers might find ways to indirectly influence DVWA activity by targeting upstream regulators or downstream effectors in the pathways it's involved in.\n",
       "*   **Biomarker Potential:** DVWA expression levels *could* potentially be used as a biomarker to predict prognosis or response to therapy in the future, although this is still speculative.\n",
       "\n",
       "**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. Because research is always ongoing, new information could emerge that changes our understanding of DVWA.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: LOC100131726\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for LOC100131726:\n",
       "\n",
       "Okay, let's break down what we can find out about LOC100131726.  It's crucial to understand that **LOC100131726 is a *predicted* gene, meaning its function is inferred from sequence similarity to other genes, but it hasn't been extensively studied.**  This significantly limits the information available.  Therefore, many of the answers will be based on *inferences* and *predictions*, and may not be definitive or fully validated.\n",
       "\n",
       "Here's what we can gather:\n",
       "\n",
       "**Gene: LOC100131726**\n",
       "\n",
       "Based on what's available from databases like NCBI and UniProt (keeping in mind that the information is limited), here's the likely scenario:\n",
       "\n",
       "*   **Predicted/Probable Identity:** Based on BLAST searches of the sequence, LOC100131726 is frequently annotated as a pseudogene or a gene similar to the human gene *GOLGA8A*. Therefore, this query assumes that LOC100131726 is the bovine ortholog of GOLGA8A.\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "Because it is an uncharacterized bovine gene, no drugs are directly targeting it. *If* it is the bovine ortholog to GOLGA8A, there will still be no known drugs that directly target it.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "N/A\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "N/A\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "If LOC100131726 is the bovine ortholog to GOLGA8A, we can infer its function:\n",
       "\n",
       "*   GOLGA8A belongs to the golgin family of proteins that are localized to the Golgi apparatus. Golgins are involved in maintaining Golgi structure and in vesicle trafficking.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "N/A\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "N/A\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "N/A\n",
       "\n",
       "**Important Considerations and Caveats:**\n",
       "\n",
       "*   **Limited Data:**  The biggest issue is the lack of research specifically on LOC100131726.  Predictions based on sequence similarity are helpful starting points, but *experimental validation* is essential.\n",
       "*   **Species Differences:**  Even if LOC100131726 is similar to a human gene, there can be significant differences in function and regulation between species.\n",
       "*   **Dynamic Field:**  Genomics and proteomics are constantly evolving. New information about LOC100131726 could emerge in the future.\n",
       "\n",
       "**In Summary:**\n",
       "\n",
       "While LOC100131726 exists as a predicted gene, there is currently insufficient information to describe its function, drug targets, or involvement in cancer. Further research is required to confirm its identity and properties.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: C10orf67\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for C10orf67:\n",
       "\n",
       "Okay, let's break down the information regarding the C10orf67 gene.  It's important to note that information about this gene is limited, and it's not a well-characterized target for existing drugs.  Much of the information is based on research and potential implications.\n",
       "\n",
       "**Gene: C10orf67**\n",
       "\n",
       "Before directly answering your questions, it's crucial to acknowledge a few points:\n",
       "\n",
       "*   **Limited Data:** There is relatively little published, peer-reviewed data specifically focused on C10orf67 as a drug target.  Most information is derived from genomic studies, protein structure prediction, and bioinformatics analysis, rather than extensive in vitro or in vivo experimentation with drugs.\n",
       "*   **Potential, Not Established:** Therefore, many of the answers below are based on *potential* interactions and *possible* therapeutic strategies, rather than established clinical practice.\n",
       "*   **Ongoing Research:** This gene is likely under investigation, so the information available may change as research progresses.\n",
       "\n",
       "Here's what we can currently infer:\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "Due to the limited knowledge about C10orf67, there are no established \"major drugs\" specifically designed to target it. However, potential avenues of therapeutic intervention include:\n",
       "\n",
       "*   **Hypothetical Inhibitors:** If C10orf67 encodes an enzyme or protein with a specific function, small-molecule inhibitors could be designed to block its activity. However, identification of its precise function is a necessary prerequisite.\n",
       "*   **Gene Therapy/RNA Interference (RNAi):** Antisense oligonucleotides or siRNA could potentially be used to inhibit the expression of the C10orf67 gene.\n",
       "*   **Immunotherapies (Indirect):** If C10orf67 expression leads to altered cell surface markers or immune evasion, immunotherapies could indirectly target cells expressing C10orf67.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "*   **Small-molecule Inhibitors (Hypothetical):** These would bind directly to the protein product of C10orf67, typically at an active site or allosteric site, to disrupt its function.\n",
       "*   **Antisense Oligonucleotides/siRNA:** These would bind to the mRNA transcript of C10orf67, preventing its translation into protein (RNAi) or causing its degradation (antisense).\n",
       "*   **Immunotherapies:** Antibodies or engineered T-cells would recognize cell surface markers associated with C10orf67 expression, leading to immune-mediated cell death.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "*   **Small-molecule Inhibitors:** The mechanism involves disrupting the protein's function.  If it's an enzyme, the inhibitor might block the active site, preventing substrate binding and catalysis. If it's a structural protein, the inhibitor might disrupt its interaction with other proteins.\n",
       "*   **Antisense Oligonucleotides/siRNA:**\n",
       "    *   *Antisense:* These bind to the mRNA via complementary base pairing, preventing ribosome binding and translation.  They can also recruit RNase H, which degrades the mRNA.\n",
       "    *   *siRNA:* These are processed by the cell's RNA interference machinery into smaller fragments that guide the RISC (RNA-induced silencing complex) to the target mRNA, leading to its degradation or translational repression.\n",
       "*   **Immunotherapies:** These work by stimulating the immune system to recognize and eliminate cancer cells. Antibodies can mark cancer cells for destruction by other immune cells (antibody-dependent cell-mediated cytotoxicity - ADCC) or activate complement (complement-dependent cytotoxicity - CDC). Engineered T-cells (e.g., CAR-T cells) are genetically modified to recognize specific cancer cell surface antigens, directly killing the cancer cells.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "*   Based on bioinformatics analysis, C10orf67 (chromosome 10 open reading frame 67) is predicted to be involved in RNA binding and splicing, with potential roles in the DNA damage response and mRNA metabolism.\n",
       "*   It may interact with the spliceosome or participate in mRNA processing.\n",
       "*   Research suggests C10orf67 could be involved in regulating the cell cycle, making it relevant in cancer studies.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "Since there are no established therapies specifically targeting C10orf67, this is speculative.  However, if therapies were developed, they could potentially be combined with:\n",
       "\n",
       "*   **Chemotherapy:**  Targeting C10orf67 could sensitize cancer cells to chemotherapy or overcome resistance mechanisms.\n",
       "*   **Radiation Therapy:**  If C10orf67 is involved in DNA damage repair, inhibiting it could make cancer cells more susceptible to radiation.\n",
       "*   **Other Targeted Therapies:**  Combination would depend on the specific cancer type and the other pathways involved.\n",
       "*   **Immunotherapy:** Combining with immunotherapies might enhance the immune response against cancer cells expressing C10orf67.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "Again, this is largely hypothetical.  However, if therapies targeting C10orf67 were available:\n",
       "\n",
       "*   **Cancer Stage:**\n",
       "    *   *Early Stage:*  Targeting C10orf67 could be used as an adjuvant therapy after surgery or radiation to prevent recurrence.\n",
       "    *   *Advanced Stage:*  Could be used in combination with other therapies to control tumor growth and prolong survival.\n",
       "*   **Patient Profile:**\n",
       "    *   *Genetic Markers:*  The expression level of C10orf67 or the presence of specific mutations in the gene could be used to select patients who are most likely to respond to therapy.\n",
       "    *   *Other Biomarkers:*  The presence of other biomarkers related to DNA damage repair or RNA processing could also be used to personalize treatment.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "*   **Cancers Associated:**\n",
       "    *   Studies have implicated C10orf67 in various cancers, including melanoma, lung, and breast cancer, due to its potential role in cell growth regulation and DNA damage response.\n",
       "*   **Treatment Options:**\n",
       "    *   Current treatment options for these cancers do not directly target C10orf67. Standard treatments include surgery, radiation therapy, chemotherapy, targeted therapies (e.g., EGFR inhibitors in lung cancer, HER2 inhibitors in breast cancer), and immunotherapy.\n",
       "    *   Research suggests that lowering C10orf67 expression can sensitize cancer cells to certain drugs, such as BRAF inhibitors for melanoma, offering a potential strategy for overcoming resistance.\n",
       "    *   Research is ongoing to identify other cancers where C10orf67 plays a significant role.\n",
       "\n",
       "**In summary:**\n",
       "\n",
       "While C10orf67 is an interesting target, current knowledge is limited, and there are no established drugs specifically targeting it.  However, research is ongoing, and future studies may reveal new therapeutic opportunities. The information provided is speculative and based on current scientific understanding. As research advances, a more comprehensive picture of C10orf67 and its role in cancer, as well as potential treatment strategies, will emerge.\n"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“¡ Querying Gemini for gene: MGC27382\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "### ðŸ§  Gemini's Response for MGC27382:\n",
       "\n",
       "Okay, let's break down the information regarding the gene MGC27382.  It's important to note that **information on MGC27382 is quite limited, and its function is not fully understood.** Therefore, the answers below are based on current research and may evolve as more data becomes available.\n",
       "\n",
       "**Important Disclaimer:** *This information is for educational purposes only and should not be considered medical advice. Consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment.*\n",
       "\n",
       "**1. What are the major drugs that target this gene?**\n",
       "\n",
       "Because the function of MGC27382 is not well defined, there are **currently no drugs specifically designed to target MGC27382 or its protein product.** It's unlikely that there are any drugs on the market that directly bind to or inhibit/activate this gene or protein at this time.\n",
       "\n",
       "**2. How does each drug interact with the gene or protein product?**\n",
       "\n",
       "N/A as there are no targeted drugs.\n",
       "\n",
       "**3. What's the biological mechanism of each interaction?**\n",
       "\n",
       "N/A as there are no targeted drugs.\n",
       "\n",
       "**4. What is the gene's molecular function?**\n",
       "\n",
       "Based on available information, the molecular function of MGC27382 is not well-defined.  Here's what we can glean from databases:\n",
       "\n",
       "*   **Limited Data:**  MGC27382 is a protein coding gene.\n",
       "*   **Protein function:** Its protein product is part of the UPF0565 family. UPF0565 is a family of proteins with unknown function.\n",
       "*   **Potential functions:**  More recent studies suggest a potential role in cell cycle regulation or DNA damage response, but these are preliminary and require further investigation.\n",
       "\n",
       "**5. How are therapies involving this gene combined in treatments?**\n",
       "\n",
       "Since there are no direct therapies targeting MGC27382, this question is not directly applicable.  However, if MGC27382 is found to be involved in a specific pathway relevant to cancer (e.g., cell cycle, DNA repair), it *could* become relevant as a biomarker for response to treatments targeting that pathway. For example, if MGC27382 expression levels correlate with sensitivity or resistance to chemotherapy, it could be used in treatment decisions.\n",
       "\n",
       "**6. How do treatments vary by cancer stage or patient profile?**\n",
       "\n",
       "Again, without specific treatments for MGC27382, this question isn't directly relevant.  Standard cancer treatments (surgery, radiation, chemotherapy, targeted therapies for *other* genes/proteins) are chosen based on the type of cancer, stage, grade, patient's overall health, and other biomarkers *known* to be relevant to that cancer.\n",
       "\n",
       "**7. What cancers are associated with this gene, and what are the treatment options?**\n",
       "\n",
       "*   **Cancers Associated:** There is evidence suggesting it may be associated with cancer development and progression; however, definitive links are lacking.\n",
       "*   **Treatment Options:** Because there are no direct therapies against MGC27382 or its protein, the treatment options would focus on the *type* of cancer a patient has. This will include a combination of:\n",
       "    *   **Surgery:** To remove the tumor.\n",
       "    *   **Radiation Therapy:** To kill cancer cells using high-energy rays.\n",
       "    *   **Chemotherapy:** To kill cancer cells using drugs.\n",
       "    *   **Targeted Therapy:** Drugs that target specific proteins or pathways involved in cancer growth (but not MGC27382 directly, as no such drugs exist).\n",
       "    *   **Immunotherapy:** To boost the body's immune system to fight cancer.\n",
       "\n",
       "**In Summary:**\n",
       "\n",
       "MGC27382 is a gene of poorly understood function. As a result, there are no known drugs that directly target this gene or its protein product.  Future research is needed to determine its exact role in cellular processes and its potential as a therapeutic target.  Currently, treatment decisions are based on the standard of care for the specific type of cancer, and MGC27382 doesn't directly factor into those decisions.\n",
       "\n",
       "**Important Next Steps in Research (if you are following this for research purposes):**\n",
       "\n",
       "1.  **Determine the protein's function:**  Experiments to understand what MGC27382's protein product actually does in the cell are critical.\n",
       "2.  **Identify interacting partners:**  Which other proteins does MGC27382 interact with?  This can provide clues to its function.\n",
       "3.  **Investigate expression patterns:**  Where and when is MGC27382 expressed in different tissues and at different stages of development?  Are there changes in expression in cancer cells compared to normal cells?\n",
       "4.  **Loss-of-function and gain-of-function studies:** What happens when MGC27382 is knocked out (deleted) or overexpressed? This provides insight to its functional role.\n",
       "5.  **Animal models:**  If MGC27382 is implicated in cancer in cell culture experiments, studies in animal models can help to validate its role and explore potential therapeutic strategies."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import requests\n",
    "import json\n",
    "import os\n",
    "from IPython.display import display, Markdown\n",
    "import concurrent.futures\n",
    "\n",
    "# ðŸ§  Class to query Gemini with top 10 genes\n",
    "class GeminiAutoQuery:\n",
    "    def __init__(self, genes):\n",
    "        self.genes = genes[:10]  # âœ… Ensure only top 10 genes are used\n",
    "        self.api_key = os.getenv(\"GEMINI_API_KEY\", \"AIzaSyA-TsTWcAYrMb4mck9dTelfX0SlwBTEKhg\")  # Use environment variable for security\n",
    "        self.url = f\"https://generativelanguage.googleapis.com/v1beta/models/gemini-2.0-flash:generateContent?key={self.api_key}\"\n",
    "\n",
    "    def _build_prompt(self, gene):\n",
    "        return (\n",
    "            f\"Gene: {gene}\\n\\n\"\n",
    "            \"1. What are the major drugs that target this gene?\\n\"\n",
    "            \"2. How does each drug interact with the gene or protein product?\\n\"\n",
    "            \"3. What's the biological mechanism of each interaction?\\n\"\n",
    "            \"4. What is the gene's molecular function?\\n\"\n",
    "            \"5. How are therapies involving this gene combined in treatments?\\n\"\n",
    "            \"6. How do treatments vary by cancer stage or patient profile?\\n\"\n",
    "            \"7. What cancers are associated with this gene, and what are the treatment options?\\n\"\n",
    "        )\n",
    "\n",
    "    def _ask_with_timeout(self, prompt, timeout=60):\n",
    "        headers = {\n",
    "            \"Content-Type\": \"application/json\"\n",
    "        }\n",
    "        data = {\n",
    "            \"contents\": [{\n",
    "                \"parts\": [{\"text\": prompt}]\n",
    "            }]\n",
    "        }\n",
    "\n",
    "        try:\n",
    "            response = requests.post(self.url, headers=headers, data=json.dumps(data), timeout=timeout)\n",
    "            if response.status_code == 200:\n",
    "                reply = response.json()\n",
    "                return reply['candidates'][0]['content']['parts'][0]['text']\n",
    "            else:\n",
    "                raise Exception(f\"API Error: {response.status_code}, {response.text}\")\n",
    "        except requests.exceptions.Timeout:\n",
    "            raise concurrent.futures.TimeoutError(f\"Request timed out.\")\n",
    "        except Exception as e:\n",
    "            raise e\n",
    "\n",
    "    def ask_gemini(self):\n",
    "        for gene in self.genes:\n",
    "            prompt = self._build_prompt(gene)\n",
    "            try:\n",
    "                print(f\"ðŸ“¡ Querying Gemini for gene: {gene}\")\n",
    "                response_text = self._ask_with_timeout(prompt, timeout=60)\n",
    "                display(Markdown(f\"### ðŸ§  Gemini's Response for {gene}:\\n\\n{response_text}\"))\n",
    "            except concurrent.futures.TimeoutError:\n",
    "                print(f\"âŒ Timeout for gene: {gene}\")\n",
    "            except Exception as e:\n",
    "                print(f\"âŒ Gemini API Error for {gene}: {str(e)}\")\n",
    "\n",
    "gq = GeminiAutoQuery(top_genes_combined)\n",
    "gq.ask_gemini()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b44cc9fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "pathway_df = pd.read_csv('/Users/hershit.rustagi/Desktop/copy.csv')  # Your file\n",
    "pathway_df = pathway_df[['DB_Object_Symbol', 'GO_ID']].dropna().drop_duplicates()\n",
    "pathway_df.columns = ['Gene', 'Pathway']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "3b3ffe12",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ”¬ Running Early vs Normal Analysis...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/hershit.rustagi/Documents/MajorProject/.venv/lib/python3.9/site-packages/scipy/stats/_axis_nan_policy.py:531: RuntimeWarning: Precision loss occurred in moment calculation due to catastrophic cancellation. This occurs when the data are nearly identical. Results may be unreliable.\n",
      "  res = hypotest_fun_out(*samples, **kwds)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ”¬ Running Late vs Normal Analysis...\n",
      "\n",
      "\n",
      "ðŸ§¬ Top 100 Significant Genes: 11\n",
      "\n",
      "ðŸ“Š Top 100 Gene-to-Pathway Mapping (Grouped):\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/hershit.rustagi/Documents/MajorProject/.venv/lib/python3.9/site-packages/scipy/stats/_axis_nan_policy.py:531: RuntimeWarning: Precision loss occurred in moment calculation due to catastrophic cancellation. This occurs when the data are nearly identical. Results may be unreliable.\n",
      "  res = hypotest_fun_out(*samples, **kwds)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Gene</th>\n",
       "      <th>Pathway</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>BCL2L10</td>\n",
       "      <td>GO:0001836, GO:0005509, GO:0005515, GO:0005634...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>C10orf67</td>\n",
       "      <td>GO:0005515, GO:0005739</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>HBG1</td>\n",
       "      <td>GO:0004601, GO:0005344, GO:0005829, GO:0005833...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>LGSN</td>\n",
       "      <td>GO:0003824, GO:0004356, GO:0005737, GO:0005886...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>LUZP4</td>\n",
       "      <td>GO:0003723, GO:0005515, GO:0005634, GO:0005737...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>SNCB</td>\n",
       "      <td>GO:0004859, GO:0005509, GO:0005515, GO:0005737...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>WFDC5</td>\n",
       "      <td>GO:0004867, GO:0005515, GO:0005576, GO:0005615...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Gene                                            Pathway\n",
       "0   BCL2L10  GO:0001836, GO:0005509, GO:0005515, GO:0005634...\n",
       "1  C10orf67                             GO:0005515, GO:0005739\n",
       "2      HBG1  GO:0004601, GO:0005344, GO:0005829, GO:0005833...\n",
       "3      LGSN  GO:0003824, GO:0004356, GO:0005737, GO:0005886...\n",
       "4     LUZP4  GO:0003723, GO:0005515, GO:0005634, GO:0005737...\n",
       "5      SNCB  GO:0004859, GO:0005509, GO:0005515, GO:0005737...\n",
       "6     WFDC5  GO:0004867, GO:0005515, GO:0005576, GO:0005615..."
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "try:\n",
    "    print(\"\\nðŸ”¬ Running Early vs Normal Analysis...\\n\")\n",
    "    early_results = calculate_differential_expression(df_early, df_normal, 'Early')\n",
    "    sig_early_genes = early_results[early_results['Significant_Early']].sort_values(\n",
    "        by='P_Value_Early'\n",
    "    )['Gene'].tolist()\n",
    "\n",
    "    print(\"\\nðŸ”¬ Running Late vs Normal Analysis...\\n\")\n",
    "    late_results = calculate_differential_expression(df_late, df_normal, 'Late')\n",
    "    sig_late_genes = late_results[late_results['Significant_Late']].sort_values(\n",
    "        by='P_Value_Late'\n",
    "    )['Gene'].tolist()\n",
    "\n",
    "    all_sig_genes = list(set(sig_early_genes + sig_late_genes))\n",
    "    top_100_genes = all_sig_genes[:11]\n",
    "    print(f\"\\nðŸ§¬ Top 100 Significant Genes: {len(top_100_genes)}\")\n",
    "\n",
    "    matched_pathways = pathway_df[pathway_df['Gene'].isin(top_100_genes)]\n",
    "\n",
    "    # Group by gene and join multiple GO terms into a single string\n",
    "    grouped_pathways = matched_pathways.groupby('Gene')['Pathway'].apply(\n",
    "        lambda x: ', '.join(sorted(set(x)))\n",
    "    ).reset_index()\n",
    "\n",
    "    print(\"\\nðŸ“Š Top 100 Gene-to-Pathway Mapping (Grouped):\")\n",
    "    display(grouped_pathways)\n",
    "\n",
    "except Exception as e:\n",
    "    print(f\"âŒ Error: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "218bdf0f",
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_go_name(go_id):\n",
    "    url = f\"https://www.ebi.ac.uk/QuickGO/services/ontology/go/terms/{go_id}\"\n",
    "    try:\n",
    "        response = requests.get(url, timeout=10)\n",
    "        response.raise_for_status()\n",
    "        results = response.json()\n",
    "        return results['results'][0]['name']\n",
    "    except Exception as e:\n",
    "        print(f\"âŒ Error for {go_id}: {e}\")\n",
    "        return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "f3848d94",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "ðŸ” Fetching GO Names: 100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 78/78 [00:47<00:00,  1.64it/s]\n",
      "/var/folders/2y/dk31s6h54731st5wr76lzszh0000gp/T/ipykernel_67907/2319921128.py:11: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  matched_pathways['Pathway_Name'] = matched_pathways['Pathway'].progress_apply(cached_fetch_go_name)\n"
     ]
    }
   ],
   "source": [
    "go_name_cache = {}\n",
    "\n",
    "def cached_fetch_go_name(go_id):\n",
    "    if go_id in go_name_cache:\n",
    "        return go_name_cache[go_id]\n",
    "    name = fetch_go_name(go_id)\n",
    "    go_name_cache[go_id] = name\n",
    "    return name\n",
    "\n",
    "tqdm.pandas(desc=\"ðŸ” Fetching GO Names\")\n",
    "matched_pathways['Pathway_Name'] = matched_pathways['Pathway'].progress_apply(cached_fetch_go_name)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "e478b092",
   "metadata": {},
   "outputs": [],
   "source": [
    "matched_pathways_clean = matched_pathways.dropna(subset=[\"Pathway_Name\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "f61c5741",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "### ðŸ§¬ Genes with All Associated Pathways (Full View)"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Gene</th>\n",
       "      <th>Pathway_Name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>BCL2L10</td>\n",
       "      <td>apoptotic process, calcium ion binding, caspase binding, channel activity, cytoplasm, cytoskeleton, cytosol, endoplasmic reticulum, extrinsic apoptotic signaling pathway in absence of ligand, female gamete generation, intrinsic apoptotic signaling pathway in response to DNA damage, membrane, microtubule organizing center organization, mitochondria-associated endoplasmic reticulum membrane contact site, mitochondrial outer membrane, mitochondrion, negative regulation of apoptotic process, nuclear membrane, nucleus, positive regulation of apoptotic process, protein binding, regulation of apoptotic process, release of cytochrome c from mitochondria, spermatogenesis, spindle, transmembrane transport</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>C10orf67</td>\n",
       "      <td>mitochondrion, protein binding</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>HBG1</td>\n",
       "      <td>carbon dioxide transport, cellular oxidant detoxification, cytosol, haptoglobin binding, haptoglobin-hemoglobin complex, heme binding, hemoglobin alpha binding, hemoglobin complex, hydrogen peroxide catabolic process, metal ion binding, oxygen binding, oxygen carrier activity, oxygen transport, peroxidase activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>LGSN</td>\n",
       "      <td>catalytic activity, cytoplasm, glutamine biosynthetic process, glutamine synthetase activity, membrane, nitrogen utilization, plasma membrane</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>LUZP4</td>\n",
       "      <td>RNA binding, cytoplasm, mRNA transport, nucleus, protein binding</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>SNCB</td>\n",
       "      <td>axon terminus, calcium ion binding, chemical synaptic transmission, cuprous ion binding, cytoplasm, cytosol, dopamine metabolic process, inclusion body, negative regulation of neuron apoptotic process, neuron apoptotic process, neuronal cell body, phospholipase inhibitor activity, protein binding, synapse, synapse organization, synaptic vesicle endocytosis, transition metal ion binding</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>WFDC5</td>\n",
       "      <td>antibacterial humoral response, extracellular region, extracellular space, innate immune response, peptidase inhibitor activity, protein binding, serine-type endopeptidase inhibitor activity</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Gene  \\\n",
       "0   BCL2L10   \n",
       "1  C10orf67   \n",
       "2      HBG1   \n",
       "3      LGSN   \n",
       "4     LUZP4   \n",
       "5      SNCB   \n",
       "6     WFDC5   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Pathway_Name  \n",
       "0  apoptotic process, calcium ion binding, caspase binding, channel activity, cytoplasm, cytoskeleton, cytosol, endoplasmic reticulum, extrinsic apoptotic signaling pathway in absence of ligand, female gamete generation, intrinsic apoptotic signaling pathway in response to DNA damage, membrane, microtubule organizing center organization, mitochondria-associated endoplasmic reticulum membrane contact site, mitochondrial outer membrane, mitochondrion, negative regulation of apoptotic process, nuclear membrane, nucleus, positive regulation of apoptotic process, protein binding, regulation of apoptotic process, release of cytochrome c from mitochondria, spermatogenesis, spindle, transmembrane transport  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    mitochondrion, protein binding  \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                       carbon dioxide transport, cellular oxidant detoxification, cytosol, haptoglobin binding, haptoglobin-hemoglobin complex, heme binding, hemoglobin alpha binding, hemoglobin complex, hydrogen peroxide catabolic process, metal ion binding, oxygen binding, oxygen carrier activity, oxygen transport, peroxidase activity  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     catalytic activity, cytoplasm, glutamine biosynthetic process, glutamine synthetase activity, membrane, nitrogen utilization, plasma membrane  \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  RNA binding, cytoplasm, mRNA transport, nucleus, protein binding  \n",
       "5                                                                                                                                                                                                                                                                                                                              axon terminus, calcium ion binding, chemical synaptic transmission, cuprous ion binding, cytoplasm, cytosol, dopamine metabolic process, inclusion body, negative regulation of neuron apoptotic process, neuron apoptotic process, neuronal cell body, phospholipase inhibitor activity, protein binding, synapse, synapse organization, synaptic vesicle endocytosis, transition metal ion binding  \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    antibacterial humoral response, extracellular region, extracellular space, innate immune response, peptidase inhibitor activity, protein binding, serine-type endopeptidase inhibitor activity  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Combine multiple rows per gene into one line\n",
    "grouped_pathways = matched_pathways_clean.groupby('Gene')['Pathway_Name'].apply(lambda x: ', '.join(sorted(set(x)))).reset_index()\n",
    "\n",
    "# Ensure full column display in notebook\n",
    "pd.set_option('display.max_colwidth', None)\n",
    "\n",
    "# Then display the full grouped data again\n",
    "display(Markdown(\"### ðŸ§¬ Genes with All Associated Pathways (Full View)\"))\n",
    "display(grouped_pathways.head(1000))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
